Neuralink

Brain-Computer Interfaces · Neurotechnology · Medical Devices

Milestone

Neuralink unveils Telepathy and Blindsight, its first two products

The vision-restoring implant is engineering-complete but unproven in humans, leaving regulatory approval as the real bottleneck to launch.

• Elon Musk posted on X on October 29-30, 2026 naming Neuralink's first two commercial products: Telepathy, a thought-based communication interface, and Blindsight, a vision-restoration implant.
• Neuralink is Musk's brain-computer interface company, implanting electrode arrays in the brain to let paralyzed patients control devices and, eventually, to restore sight to the blind.
• Telepathy runs on 1,024 electrodes across 64 hair-thin polyimide threads and is already in human testing under the PRIME Study, letting quadriplegic participants type, play games and drive robotic arms by thought.
• Blindsight received FDA Breakthrough Device Designation in September 2024 but remains pre-clinical; Musk says it is ready engineering-wise and is now waiting on regulatory clearance.
• Neuralink engineers recently spent 72 hours at a VOICE study participant's home prototyping speech features, building on an earlier report of an ALS patient reaching 75 words per minute with thought-to-speech decoding.
• Neither product has completed pivotal trials for full approval, and Blindsight has not yet demonstrated restored vision in any human patient, despite Musk's engineering-ready claim.
• Giving its implants distinct commercial names signals Neuralink is splitting its single research platform into separate regulatory and go-to-market paths for motor control and vision restoration.